#United States #Oakland #GOJO #PURELL #Clorox

Clorox Company Reports Q4 and FY 2026 Results and FY 2027 Outlook

The Clorox Company (NYSE: CLX) has recently announced its fourth quarter results for fiscal year 2026, concluding on June 30, 2026. The company reported some challenges this year, with net sales dropping 2% to $1.95 billion. However, the acquisition of GOJO Industries, now operating as Clorox Purell, added approximately 10 points to the sales figure. The organic sales actually decreased by 13%, primarily due to the effects of prior shipments related to the implementation of their new ERP system.

Key Highlights

1. Quarterly Performance: The company reported a gross margin decline from 46.5% to 41.3%, influenced by factors such as inventory adjustments stemming from the GOJO acquisition and increased costs for commodities and logistics. The diluted net earnings per share (EPS) showcased a significant 50% drop to $1.34, down from $2.68 compared to the same quarter last year.

2. Adjusted EPS: The adjusted EPS decreased by 42% to $1.66, demonstrating ongoing pressure from reduced sales and lower gross margin.

3. Strategic Growth: The fiscal year saw Clorox strengthening its business resilience through key acquisitions and by expanding its product range. Notably, the acquisition of GOJO brought new health and hygiene products into their portfolio, which is now a significant portion of Clorox's net sales.

Operational Developments

The company made several strategic investments throughout FY 2026:

• - Acquisition of GOJO: This acquisition is expected to create growth synergies, leveraging complementary strengths in health and hygiene products.
• - ERP Implementation: Clorox completed its U.S. ERP system implementation, enhancing operational efficiency and decision-making capabilities.
• - Focus on Innovation: Clorox has increased its investments nearly doubling innovation across its expanded portfolio with new product launches in various sectors.

Segment Performance

The quarterly report indicated varying performances across different segments:

• - Health and Wellness: This segment experienced a net sales increase of 16%, driven largely by the acquisition of GOJO. However, when adjusted for previous stock movements, organic sales fell by 12%.
• - Household Products: Net sales decreased by 18%, affected by lower volume and an unfavorable price mix. The earnings before interest and taxes (EBIT) saw a significant decline.
• - Lifestyle Segment: This part of the business reported a 17% decrease in net sales, mainly due to a lower sales volume.
• - International Sales: Notably, international sales rose by 4%, driven by favorable exchange rates, showing potential for growth outside the U.S.

Looking Ahead to 2027

As Clorox embarks on fiscal year 2027, expectations are cautious yet optimistic:

• - Sales Growth Projection: The company anticipates a 13% to 14% increase in net sales compared to the previous year, buoyed by the GOJO acquisition.
• - Organic Sales Forecast: An increase of about 3.5% to 4.5% is expected, supported by recovering from the previous year’s inventory challenges.
• - Challenges Ahead: Clorox is braced for ongoing cost volatility and changes in consumer behavior, necessitating a disciplined approach in executing their strategies.

Conclusion

Clorox's results for FY 2026 reflect a year of adaptation and growth amid consumer and economic pressures. The strategic guidance and recent acquisitions position the company to navigate future challenges successfully as they work towards organic sales recovery. The insights from this fiscal year will be crucial as they aim to maximize shareholder value while catering to evolving consumer demands.